Evonik raised Rexim® amino and keto acid prices by up to 15 percent due to rising energy, material, and freight costs.
Evonik has announced a price increase of up to 15 percent for selected products in its Rexim® portfolio of pharmaceutical amino and keto acids. The company said the decision comes in response to continued increases in operating costs, including higher energy prices, rising raw material expenses, and elevated freight charges affecting global supply chains. The revised pricing will take effect immediately across all international markets.
The Rexim® range is widely used in the pharmaceutical and healthcare sectors, particularly in medical nutrition and specialized therapeutic applications. By implementing this adjustment, Evonik aims to manage the growing financial pressures impacting production and logistics while maintaining consistent product quality and supply reliability for customers worldwide.
Despite the increase, the company confirmed that all current contracts and previously agreed supply arrangements will continue to be honored under their existing terms. This assurance is intended to provide stability to customers and business partners who rely on long-term procurement agreements and uninterrupted deliveries.
The move reflects broader challenges currently facing the global chemical and pharmaceutical ingredients industry, where manufacturers are experiencing sustained inflation in utilities, transportation, and feedstock costs. Companies across the sector have increasingly been forced to review pricing structures to offset these pressures and protect operational sustainability.
Evonik emphasized that the adjustment is necessary to support ongoing manufacturing efficiency and supply continuity within its pharmaceutical solutions business. The company remains focused on serving customers with high-quality amino and keto acid products while adapting to changing market conditions and economic realities impacting the global specialty chemicals industry.
